新辅助免疫检查点抑制剂给药时间与可切缘III-IV期黑色素瘤生存相关但与病理缓解无关:一项回顾性队列研究
该回顾性队列研究纳入265例在瑞典四家学术中心接受新辅助ICI治疗的可切缘III-IV期皮肤黑色素瘤患者,按两次输注时间分为早间组、混合组和午后组。主要终点主要病理缓解率组间相似(早间47%,混合44%,午后40%;p=0.68)。中位随访17.4个月后,早间给药相比午后给药与更低的远处转移、黑色素瘤特异性死亡和总死亡风险相关,但无事件生存无显著差异。
要点
- 新辅助ICI给药时间与主要病理缓解率无关。
- 早间给药相比午后给药与更优的DMFS、MSS和OS相关。
- EFS在早间与午后给药间无显著差异。
核心结论
- 新辅助ICI给药时间与病理缓解无关,但午后给药与更差的生存结局相关。
- 这些发现提示治疗时机可能影响长期结局,但仍需前瞻性验证。
研究设计与样本
- 回顾性队列研究,纳入265例在瑞典四家学术中心接受新辅助ICI治疗的可切缘III-IV期皮肤黑色素瘤患者。
- 按两次输注时间分为早间组(两次均<12:00,n=94)、混合组(一次<12:00一次≥12:00,n=96)和午后组(两次均≥12:00,n=75)。
- 主要终点为主要病理缓解,次要终点包括EFS、DMFS、MSS和OS,采用逻辑回归和Cox模型评估关联。
主要发现
- 主要病理缓解率组间相似:早间47%,混合44%,午后40%(p=0.68)。
- 中位随访17.4个月,早间给药相比午后给药与更低的DMFS风险相关(HR 0.47,95%CI 0.23-0.96)。
- 早间给药相比午后给药与更低的MSS风险相关(HR 0.18,95%CI 0.04-0.71)。
- 早间给药相比午后给药与更低的OS风险相关(HR 0.13,95%CI 0.04-0.50)。
- EFS在早间与午后给药间无显著差异(HR 0.58,95%CI 0.31-1.08)。
临床怎么用
- 对于接受新辅助ICI的可切缘III-IV期黑色素瘤患者,给药时间可能影响长期生存,早间给药或可优先考虑。
- 目前证据来自回顾性研究,尚不能据此改变临床实践,需前瞻性研究验证。
局限性
- 回顾性队列研究设计,存在选择偏倚和混杂因素可能。
- 样本量有限(265例),随访时间较短(中位17.4个月)。
- 给药时间分组基于两次输注,未考虑其他时间因素。
- 需要前瞻性验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Circadian rhythms regulate immune cell trafficking and function, and emerging clinical data suggest that the timing of immune checkpoint inhibitor (ICI) administration may influence efficacy. In advanced disease, later-day administration has been associated with inferior outcomes. Whether this applies to neoadjuvant ICI in resectable stage III-IV melanoma is unknown. METHODS: This retrospective cohort study included patients with resectable stage III-IV cutaneous melanoma treated with neoadjuvant ICI at four Swedish academic centers. Patients were categorized by timing of ICI across two infusions (morning, both <12:00; afternoon, both ≥12:00; mixed, one <12:00 and one ≥12:00). The primary endpoint was major pathological response. Secondary endpoints were event-free (EFS), distant metastasis-free (DMFS), melanoma-specific (MSS), and overall survival (OS). Associations were assessed using logistic regression and Cox models. RESULTS: A total of 265 patients were included (morning, n = 94; mixed, n = 96; afternoon, n = 75). Major pathological response rates were similar across groups (morning 47%, mixed 44%, afternoon 40%; p = 0.68). After a median follow-up of 17.4 months, morning administration was associated with a lower hazard of events across survival endpoints versus afternoon, including DMFS (HR 0.47, 95% CI 0.23-0.96), MSS (HR 0.18, 95% CI 0.04-0.71), and OS (HR 0.13, 95% CI 0.04-0.50) but not EFS (HR 0.58, 95% CI 0.31-1.08), compared with afternoon administration. Associations remained after adjustment for pathological response. CONCLUSIONS: Time of day of neoadjuvant ICI administration was not associated with pathological response. However, afternoon administration was associated with worse survival outcomes. These findings suggest treatment timing may influence long-term outcomes, although prospective validation is needed.
引用
- Nelson A, Alghaib S, Björkström K, et al. Time of day of neoadjuvant immune checkpoint inhibitor administration is associated with survival but not pathological response in resectable stage III-IV melanoma: A retrospective cohort study. Eur J Cancer. 2026. PMID: 42218102. doi:10.1016/j.ejca.2026.116833
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。